Masimo Corporation $MASI Shares Sold by Perpetual Ltd

Perpetual Ltd cut its holdings in Masimo Corporation (NASDAQ:MASI) by 49.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,648 shares of the medical equipment provider’s stock after selling 10,524 shares during the quarter. Perpetual Ltd’s holdings in Masimo were worth $1,571,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Deutsche Bank AG grew its stake in shares of Masimo by 1.5% during the 1st quarter. Deutsche Bank AG now owns 6,309 shares of the medical equipment provider’s stock valued at $1,051,000 after buying an additional 92 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Masimo by 8.6% in the first quarter. Dimensional Fund Advisors LP now owns 703,378 shares of the medical equipment provider’s stock worth $117,172,000 after buying an additional 55,658 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Masimo by 525.5% during the first quarter. American Century Companies Inc. now owns 79,176 shares of the medical equipment provider’s stock worth $13,191,000 after purchasing an additional 66,517 shares during the last quarter. Raymond James Financial Inc. increased its holdings in shares of Masimo by 1.1% in the 1st quarter. Raymond James Financial Inc. now owns 206,116 shares of the medical equipment provider’s stock valued at $34,339,000 after acquiring an additional 2,145 shares during the last quarter. Finally, Algert Global LLC bought a new position in shares of Masimo during the first quarter worth about $1,218,000. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MASI has been the topic of a number of recent analyst reports. Wall Street Zen raised Masimo from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Wells Fargo & Company restated an “overweight” rating and issued a $190.00 price objective on shares of Masimo in a research note on Friday, December 5th. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a research report on Wednesday, October 8th. Bank of America assumed coverage on Masimo in a report on Monday, November 17th. They set a “neutral” rating and a $162.00 price objective on the stock. Finally, BTIG Research lifted their price target on shares of Masimo from $198.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $189.40.

Masimo Price Performance

Shares of MASI opened at $134.04 on Friday. The company has a quick ratio of 1.92, a current ratio of 2.84 and a debt-to-equity ratio of 0.69. Masimo Corporation has a twelve month low of $131.47 and a twelve month high of $194.88. The company has a 50 day moving average of $143.93 and a 200-day moving average of $150.58. The stock has a market capitalization of $7.20 billion, a P/E ratio of -12.72, a P/E/G ratio of 1.45 and a beta of 1.26.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a positive return on equity of 33.04% and a negative net margin of 33.20%.The company had revenue of $617.00 million during the quarter. As a group, equities research analysts forecast that Masimo Corporation will post 4.1 EPS for the current fiscal year.

Masimo Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.